AstraZeneca PLC (LON:AZN) Receives Average Rating of “Moderate Buy” from Analysts

Shares of AstraZeneca PLC (LON:AZN) have received an average rating of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is £153.33.

A number of brokerages recently issued reports on AZN. Deutsche Bank Aktiengesellschaft reissued a “sell” rating and issued a £115 target price on shares of AstraZeneca in a research report on Friday, June 26th. Citigroup cut shares of AstraZeneca to a “buy” rating in a research note on Friday, July 10th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a £180 price objective on shares of AstraZeneca in a report on Friday, June 26th.

AstraZeneca Stock Performance

Shares of AstraZeneca stock opened at £126.70 on Tuesday. The firm has a market cap of £196.50 billion, a price-to-earnings ratio of 19.08, a price-to-earnings-growth ratio of 0.86 and a beta of 0.23. The stock’s 50-day moving average is £135.05 and its 200-day moving average is £140.64. AstraZeneca has a one year low of £106.99 and a one year high of £157.32. The company has a debt-to-equity ratio of 71.66, a current ratio of 0.91 and a quick ratio of 0.59.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.